Leading Barriers to Prescription Digital Therapeutics (PDTs) Adoption According to US Payers and Employers, Summer 2021 (% of respondents)
Data is from the October 2021 Pear Therapeutics and Avalere report titled, "Pear Prescription Digital Therapeutics (PDT) Digest." 40 US payers (n=30) and employers (n=10), who are familiar with PDT, were surveyed during summer 2021. 75% of the respondents was payer or pharmacy benefit managers, and 25% was employer or employer benefits consultants who represented employer self-insured groups. The payer respondents collectively represented 192 million covered lives.